Dr. Anke Caßing
Principal
About me
| Team | Life Sciences & Chemistry |
| at HTGF since | 2017 |
| my focus | Life sciences and growth investments |
| my background | PhD in biology, degree in economics |
CV
Dr. Anke Caßing has many years of experience in strategic marketing and business development in medical technology, biotechnology and in pharmaceutics. She holds a doctorate in biology and studied economics. Before joining the HTGF, she developed the product portfolios of international companies ensuring their future growth.
Four questions for …
What drives you?
Contributing to the creation of innovations, i.e. taking something from an idea to a successful product that solves customer problems.
What is special about your work at a venture capitalist?
Every day I meet inspiring people and learn something new. Every day I am challenged with everything I have already learned.
What does it mean to found in Germany?
Every startup is a further contribution to the necessary transformation of our economy and a further approach to solving urgent problems.
What distinguishes the HTGF team?
A lot of passion for startups and the startup ecosystem!
My success stories in the HTGF portfolio
PreComb Therapeutics AG is a privately held Swiss biotech company founded in 2018 by Jens M. Kelm, Peter Steiner and Olivier Mauti with the aim of developing technologies that bring …
Angiolutions specializes in device-based innovation in vascular medicine. Through its latest award-winning technology, the company aims to prevent the deadly progression of small abdominal aortic aneurysms. An abdominal aortic aneurysm …
Lymphatica Medtech develops medical devices for lymphatic disease treatment. The first product, LymphoDRAIN, is the worldwide first active lymphatic bypass for the treatment of chronic lymphedema, a disabling disease affecting …
Biograil is a Danish start-up using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device …
Pantherna Therapeutics is a privately-held biopharmaceutical company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA …
Numaferm developed a platform technology for fast, scalable and cost-efficient production of peptides and proteins, with a focus on pepteins (PEPTides & protEINS) in the range of 30-500 amino acids. …
Coramaze Technologies develops an innovative, highly differentiated, transcatheter tricuspid valve repair system, called TriPair. Headquartered in Germany with an R&D hub in Israel, we promote health equity by offering a …
Guided to exit
Development of antibody conjugate-based cancer therapeutics for solid tumors with high unmet needs that are otherwise difficult to treat Problem: Solid cancers are still very difficult to treat. Most treatments …
Purenum is a spin-off of the Fraunhofer-IFAM and develops biocompatible adhesives for medical use. As part of a BMBF project (GO-Bio 6 “mediNiK”), an adhesive was developed that can be …
RIMASYS offers prefractures specimen for educational purposes in the field of orthopedic surgery. The innovative MedTech company is setting new standards in surgical education and implant development through innovative education …
Recent posts
Zum Artikel
Lymphatica Medtech closes €17.9M Series B funding round to drive Innovation in Lymphedema Treatment
Zum Artikel
Social Media & contact
LinkedIn
Dr. Anke Caßing
Profil